Research increasingly shows that vaccines provide significant health benefits beyond preventing the specific diseases they target—known in medical terms as “off-target benefits.” These protections are particularly important for older adults whose weakening immune systems and higher rates of chronic illness put them at elevated risk of infectious disease.
The strongest evidence for cardiovascular off-target benefits dates back 25 years, showing that healthy older adults vaccinated against flu have substantially lower hospitalization risks for heart failure, pneumonia, and other respiratory infections, as well as lower risks of heart attack and stroke. These benefits predate more potent flu vaccines now recommended for older adults. A recent large Danish study found a nearly 10% decline in cardiorespiratory hospitalizations among RSV-vaccinated older adults compared to a control group. Vaccination against covid has been linked to lower risk of developing long covid.
Most provocative are findings concerning shingles vaccination and dementia reduction. In a meta-analysis published in Age and Ageing examining 21 studies involving over 104 million participants across Europe, Asia, and North America, shingles vaccination was associated with a 24% reduction in dementia risk. Flu vaccination linked to a 13% reduction, pneumococcal vaccination to a 36% reduction in Alzheimer’s risk, and Tdap vaccination to a one-third decline in dementia risk. A natural experiment in Wales in 2013 provided compelling evidence: when the first shingles vaccine became available only to people under 80, dementia rates declined by 20% over seven years in the eligible group compared with those narrowly ineligible by birth date, despite only half actually receiving vaccination.
However, vaccine uptake among older adults remains inadequate. The CDC reports approximately 31% of older adults had not received a flu shot, and only about 41% of those 75 and older had ever been vaccinated against RSV, with about a third of seniors having received the most recent covid-19 vaccine. From 2022-2024, only about 12% of those 67-74 and 8% of those 75 and older received the recommended pneumococcal vaccine.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://kffhealthnews.org/news/article/vaccines-off-target-benefits-older-adults-dementia-shingles/